Balance Sheet

Accounts Payables Accumulated Depreciation Accumulated Expenses Assets Cash & Equivalents Common Equity Current Assets Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Deferred Tax Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Notes Payables Operating Leases Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Shares Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares

Cash Flow Statement

Daily Values

Growth Metrics

Others

Avalo Therapeutics (AVTX) Current Deferred Revenue (2022 - 2023)

Avalo Therapeutics filings provide 2 years of Current Deferred Revenue readings, the most recent being $111000.0 for Q1 2023.

On a quarterly basis, Current Deferred Revenue changed N/A to $111000.0 in Q1 2023 year-over-year; TTM through Mar 2023 was $111000.0, a N/A change, with the full-year FY2022 number at $88000.0, changed N/A from a year prior.
Current Deferred Revenue hit $111000.0 in Q1 2023 for Avalo Therapeutics, up from $88000.0 in the prior quarter.
In the past five years, Current Deferred Revenue ranged from a high of $442000.0 in Q3 2022 to a low of $88000.0 in Q4 2022.